CLINICAL TRIALS PROFILE FOR VOLINANSERIN
✉ Email this page to a colleague
Clinical Trials for Volinanserin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00464061 ↗ | Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus | Terminated | Sanofi | Phase 3 | The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The objective of the substudy is to assess glycemic control in the subgroup of patients with type II diabetes mellitus. |
NCT00464243 ↗ | Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study | Completed | Sanofi | Phase 3 | The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The patients suffering from that condition frequently wake up during the night, their sleep is non restorative and they suffer from a significant distress or impairment in their daily activities consecutive to insomnia. |
NCT00495885 ↗ | Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus | Completed | Sanofi | Phase 3 | The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia. The objective of the substudy is to assess glycemic control in the subgroup of patients with type II diabetes mellitus. |
NCT00788515 ↗ | Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties | Terminated | Sanofi | Phase 3 | The primary objective is to compare the potential for next-day residual effects of volinanserin 2 mg/day and lormetazepam 1 mg/day by measuring the sleepiness in the morning using the patient's sleep questionnaire during 4 weeks of treatment in patients with chronic primary insomnia and sleep maintenance difficulties. Secondary objectives are to compare the clinical safety of both products, including the potential for rebound insomnia and withdrawal symptoms after treatment discontinuation, to compare the efficacy of both products on subjective sleep parameters and to compare the effects of both products on patient's daytime functioning. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Volinanserin
Condition Name
Clinical Trial Locations for Volinanserin
Trials by Country
Clinical Trial Progress for Volinanserin
Clinical Trial Phase
Clinical Trial Sponsors for Volinanserin
Sponsor Name